Relmada Therapeutics has entered into a $3 million agreement to purchase Sepranolone, a treatment for Tourette Syndrome, from Asarina Pharma, with a payment of $2.76 million due shortly after the agreement's effective date. The Phase 2a study of Sepranolone showed a 28% reduction in tic severity and improved quality of life for patients.